Test Price
2,800 AED✅ Home Collection Available
UNC13D Gene Hemophagocytic Lymphohistiocytosis Type 3 Genetic Test in UAE
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- ✓ Clinical Guidance: Telephonic post-test consultation with a DHA‑licensed Consultant Medical Genetics specialist for result interpretation.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The UNC13D Gene Hemophagocytic Lymphohistiocytosis Type 3 Genetic Test detects pathogenic variants in the UNC13D gene responsible for familial hemophagocytic lymphohistiocytosis type 3 (FHL3), a life‑threatening hyperinflammatory syndrome. This next‑generation sequencing (NGS) assay provides definitive molecular diagnosis, enabling targeted clinical management and family screening under the highest UAE regulatory standards.
| Feature | Our Test (UAE) | Closest Alternative |
|---|---|---|
| Precision | Full UNC13D gene sequencing with CNV detection | Targeted mutation panels or Sanger sequencing without deletion/duplication analysis |
| Methodology | Next‑Generation Sequencing (NGS) with ISO 9001:2015 validation | Conventional PCR / Sanger sequencing; may lack comprehensive coverage |
| Turnaround Time | 3–4 weeks with expedited reporting | Often 6–8 weeks without regulatory oversight |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Genetics, I emphasize that this genetic test delivers definitive molecular evidence for FHL3, yet results must always be correlated with clinical presentation, inflammatory biomarkers, and family history. A negative result does not exclude other forms of HLH, and a positive finding warrants immediate specialist referral for hematopoietic stem cell transplantation evaluation. This test transforms uncertainty into actionable clarity for families facing this devastating condition.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Medication Advisory
Do not alter or discontinue any prescribed immunosuppressant, chemotherapy, or biologic therapy without direct instruction from your treating haematologist. Test results are intended to guide clinical decisions solely under ongoing medical supervision.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Severe thrombocytopenia (platelets < 20,000/µL) that makes venipuncture unsafe; however, DNA extraction from a buccal swab or one drop of blood on an FTA card remains a viable alternative.
- ER Red Flags (seek immediate emergency care): High spiking fever unresponsive to antipyretics, acute jaundice, new‑onset seizures or altered consciousness, severe abdominal distension, or sudden cytopenias with coagulopathy. These may signal a fulminant HLH flare requiring urgent haematology intervention.
Patient FAQ & Clinical Guidance
1. What symptoms or conditions indicate I might need a UNC13D genetic test for familial HLH type 3?
Persistent fever, hepatosplenomegaly, cytopenias, and hyperferritinemia in infants or young children strongly suggest familial HLH, warranting urgent UNC13D gene analysis. Additional signs include central nervous system involvement (seizures, irritability), markedly elevated soluble IL‑2 receptor, and evidence of hemophagocytosis in bone marrow. A positive family history or consanguinity increases pre‑test probability. Early genetic diagnosis is lifesaving and guides hematopoietic stem cell transplant decisions.
2. How is the sample collected, and do I need to stop any medications before the test?
A simple blood draw, a single drop of blood on an FTA card, or a buccal swab can be used — no medication adjustments are required. Our ISO‑certified home collection team handles everything under cold‑chain conditions. Inform your physician of all current medications, but do not stop or alter dosing without medical advice. Immunosuppressive therapy does not affect detection of the germline mutation; therefore, the test remains valid regardless of treatment status.
3. What does a positive UNC13D result mean for my treatment and family planning?
A positive UNC13D variant confirms familial HLH type 3, requiring immediate haematology‑oncology consultation for curative hematopoietic stem cell transplantation (HSCT). Targeted therapy such as an anti‑IFN‑gamma monoclonal antibody may be used as a bridge to transplant. For family planning, identification of a biallelic mutation enables precise carrier testing of relatives and pre‑implantation genetic diagnosis (PGD) to prevent recurrence in future pregnancies. Genetic counseling is mandatory to interpret autosomal recessive inheritance and recurrence risks.
4. How long does it take to receive results and how are they delivered?
Results are typically available within 3–4 weeks from sample receipt. A comprehensive molecular report is delivered electronically via secure portal and followed by a telephonic consultation with a DHA‑licensed Consultant Medical Genetics who explains the findings, clinical implications, and recommended next steps in plain language.
UAE Regulatory & Data Privacy Adherence
Trusted Healthcare Compliance Framework
This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory processing is performed under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139). All clinical interpretations are reviewed by a DHA‑licensed physician under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | UNC13D Gene Hemophagocytic Lymphohistiocytosis Type 3 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood, Buccal swab, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) with Copy Number Variant (CNV) detection |
| ICD-10-CM Code | D76.1 |
| LOINC Code | 82173-8 |
| DHA Facility License & Address | DHA Facility License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians